[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pleural-effusion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pleural-effusion":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,44,81,109,139,161,183,208,231,259,280,305,326,345,377,408,438,463,489,525,554,574],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100511868","continuation-of-a-study-to-investigate-the-effect-of-thoracocentesis-on-neural-respiratory-drive-in-pleural-effusion-100511868",false,"NCT05945043","Continuation Of a Study to Investigate the Effect of Thoracocentesis on Neural Respiratory Drive in Pleural Effusion","Continuation Of a Study to Investigate the Effect of Thoracocentesis on Neural Respiratory Drive in Pleural Effusion (COSINE)","COSINE","Inclusion Criteria:\n\n* Age 18 years or above\n* Has a unilateral pleural effusion AND\n\n  1. require thoracocentesis OR\n  2. chest drain insertion (main study only) OR\n  3. has an IPC in situ (main study only)\n\nExclusion Criteria:\n\n* Inability to consent\n* Any contraindications to the proposed pleural procedure\n* Haemodynamic or clinical instability that precludes from the safe completion of required pre-procedural measurements\n* Inability to identify surface landmarks for surface EMG electrode placement\n* Past medical history of diaphragmatic paralysis (diaphragm sub study only)","ALL","18 Years",{"count":20,"type":21},124,"ESTIMATED","OBSERVATIONAL","The aim of this study is to better understand the relationship between pleural effusions and breathlessness in patients with unilateral pleural effusions and breathlessness who require pleural fluid removal for its management.",[25],"Pleural Effusion",[27,28,29,30],"Pleural effusion","Breathlessness","Neural respiratory drive","Neurophysiology","RECRUITING","2026-06-03",{"date":34,"type":35},"2026-06-04","ACTUAL",{"date":37,"type":35},"2023-11-15",{"date":39,"type":21},"2027-06-30",{"name":41,"class":42},"Guy's and St Thomas' NHS Foundation Trust","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":66,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100600274","phase-4-once-daily-intrapleural-enzyme-therapy-in-complicated-parapneumonic-effusion-or-empyema-100600274","NCT07095361","Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema","Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema (ONLY ONCE)","ONLY ONCE","Inclusion Criteria:\n\n* Written informed consent obtained from patient or patient's legally authorized representative (LAR) to participate in the study and HIPAA authorization for release of personal health information.\n* Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.\n* Age ≥ 18 years at the time of consent.\n* Patient is admitted to the hospital and with a pleural effusion that is drained with a small-bore chest tube or one that allows for administration of IET\n* Pleural fluid that is one of the following:\n\n  (i) Macroscopically purulent or pleural fluid gram stain or culture positive for bacteria (ii) potential of hydrogen (pH) \\\u003C 7.2 (iii) Pleural fluid glucose \\\u003C 60mg\u002FdL (iv) Pleural fluid Lactate Dehydrogenase (LDH) \\> 1,000 IU\u002FL\n* Patient is deemed a candidate to receive intrapleural enzyme therapy as defined by having a residual collection or persistent sepsis 24 hours after initial chest tube placement\n\nExclusion Criteria:\n\n* Known pregnancy or lactating females\n* Prisoners\n* Age \\\u003C18 years at time of consent\n* Previous treatment with intra-pleural fibrinolytic agents, DNase, or both during the same hospital admission\n* Known sensitivity or allergic reaction to DNAse or tPA\n* Coincidental stroke, major hemorrhage (requiring blood transfusions within the last 5 days), major trauma, or major surgery within the last 5 days\n* Previous pneumonectomy or active bronchopleural fistula on the affected side\n* Therapeutic systemic anticoagulation or antiplatelet agents that cannot held for more than 48 hours prior to IET administration\n* Expected survival of less than 3 months due to a pathologic condition other than that causing the pleural infection",{"count":53,"type":21},270,"INTERVENTIONAL",[56],"PHASE4","The goal of this clinical trial is to find out if giving certain medications once a day works just as well as giving them twice a day to treat infections around the lungs (called pleural infections). These medications-tissue plasminogen activator (tPA) and deoxyribonuclease (DNase)-are placed through a chest tube into the space between the lung and the chest wall to help clear out the infection.\n\nThe investigators are trying to learn:\n\n* Does using the medicine once a day work just as well as using it twice a day?\n* Are there any differences in outcomes between patients who get the medicine once a day versus twice a day?\n* Does more or less fluid remain in the chest (seen on a chest x-ray) depending on how often the medicine is given?\n\nParticipants will:\n\n* Have an infection around their lung and will already be getting normal hospital care, including a chest tube to drain the infected fluid around their lung.\n* Be asked to give permission to join the study.\n* Be randomly chosen (like flipping a coin) to get the medications either once a day or twice a day through the chest tube.",[59,60,61,62,63,64,65,25],"Pleural Infection Bacterial","Pleural Infections","Pleural Infections and Inflammations","Empyema, Pleural","Empyema","Complicated Pleural Effusion\u002F Empyema","Pleural Effusion Associated With Pulmonary Infection",[67,68,69,70],"Lytics","Intrapleural enzyme therapy","Once daily","lytic therapy","2026-05-14",{"date":73,"type":35},"2026-05-19",{"date":75,"type":35},"2025-09-11",{"date":77,"type":21},"2028-09-30",{"name":79,"class":42},"University of North Carolina, Chapel Hill",6,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":54,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":43},"100589779","16f-vs-24f-chest-drain-after-minimally-invasive-lobectomy-andor-segmentectomy-100589779","NCT06958848","16F vs 24F Chest Drain After Minimally Invasive Lobectomy and\u002For Segmentectomy","Comparison of 16F Versus 24F Chest Drain After Minimally Invasive Pulmonary Lobectomy and\u002For Segmentectomy: a Monocentre Prospective Randomized Controlled Trial","ChestDrain","Inclusion Criteria:\n\n* Informed Consent signed by the patient (all sex and gender)\n* Patients' age from ≥ 18 to no age limit at time of study inclusion\n* American Society of Anaesthesiologists (ASA) physical status classification I to IV\n* Patients with resectable non-small cell lung cancer (NSCLC) deemed operable by minimally invasive surgical technique.\n* Minimally invasive anatomical lung resections under general anaesthesia: lobectomy, lobectomy with wedge resection, lobectomy combined with segmentectomy, segmentectomy with wedge resection, bilobectomy\n\nExclusion Criteria:\n\n* Previous thoracic surgery on the same side within 3 months\n* Lung cancer complicated with pleural empyema\n* Patients with chronic pain who receive opioids\u002Fgabapentin\u002Fpregabalin\n* Patients who consume opiates\u002Fbenzodiazepines\n* Congestive heart failure NYHA Class III or IV\n* Liver cirrhosis Child-Pugh Class B and C\n* Renal insufficiency requiring dialysis and\u002For estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m2\n* Patients with coagulopathy or bleeding disorders: von Willebrand disease, Hemophilia; Thrombocytopenia (\\\u003C50 G\u002Fl), requiring platelet transfusion\n* Patients with neuralgia\n* Chest pain (site of surgery) without taking painkillers, measured by VAS while coughing \\> 10 mm\n* Not consolidated rib fractures (in the last 3 months) on the side of surgical procedure\n* Open anatomical lung resection, including pneumonectomy\n* Insertion of 2 or more chest tubes\n* Need for patient controlled intravenous anaesthesia or patient controlled epidural anaesthesia\n* Patients intubated\u002Fsedated (not suitable due to difficulties to fill out the pain survey)",{"count":20,"type":21},[91],"NA","The aim of the study is to evaluate postoperative pain in patients receiving a small-bore (16F) chest drain compared to those receiving the standard large-bore (24F) chest drain after minimally invasive pulmonary lobectomy and\u002For segmentectomy.",[94,25],"Pneumothorax",[96,97,98,99],"Lung Surgery","Chest Drainage","Minimally Invasive Thoracoscopic Lobectomy","Minimally Invasive Thoracoscopic Segmentectomy","2026-04-30",{"date":102,"type":35},"2026-05-06",{"date":104,"type":35},"2025-05-01",{"date":106,"type":21},"2027-08-30",{"name":108,"class":42},"University Hospital, Basel, Switzerland",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":4},"100635066","pleural-effusion-types-in-chronic-kidney-disease-100635066","NCT07547852","Pleural Effusion Types in Chronic Kidney Disease","Transudative and Exudative Pleural Effusion in CKD Patients","Inclusion Criteria:\n\n* Adults aged ≥18 years of either sex\n* Confirmed diagnosis of CKD Stage 3-5 based on eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m² for ≥3 months, as per KDIGO 2012 guidelines\n* Radiologically confirmed pleural effusion on chest X-ray (CXR) or thoracic ultrasound\n* Patients on hemodialysis or peritoneal dialysis, as well as those not yet on dialysis (CKD Stage 3-5 pre-dialysis)\n* Willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Patients with Acute Kidney Injury (AKI) or acute-on-chronic kidney disease without prior CKD diagnosis\n* Trauma-related pleural effusion (hemothorax, chylothorax)\n* Known active malignancy with suspected malignant effusion\n* Patients with post-surgical or iatrogenic pleural effusion\n* Patients who refuse consent or are unable to undergo thoracentesis due to coagulopathy or other contraindications\n* Pregnancy",{"count":117,"type":21},100,"The purpose of this observational study is to understand the causes of pleural effusion (a buildup of fluid around the lungs) in patients with advanced Chronic Kidney Disease (CKD Stages 3 to 5). Pleural effusion is a common complication in kidney disease, but it can be caused by many different issues, such as simple fluid overload, heart failure, or infections like tuberculosis.\n\nTo treat this fluid buildup effectively, doctors need to classify whether the fluid is a transudate (usually caused by pressure imbalances like fluid overload) or an exudate (caused by inflammation, lung disease, or infection). Standard medical formulas, known as Light's Criteria, are typically used to figure this out by comparing proteins in the fluid to proteins in the blood. However, these standard tests may sometimes misclassify the fluid in kidney disease patients because their baseline blood protein and albumin levels are often altered by their condition.\n\nResearchers in this study will enroll adult CKD patients (both on dialysis and not yet on dialysis) who have confirmed fluid around their lungs. Participants will undergo a standard, ultrasound-guided procedure called a diagnostic thoracentesis to safely draw a small amount of the chest fluid. At the same time, a routine blood sample will be taken.\n\nThe study aims to:\n\n* Compare the chest fluid to the blood sample using standard criteria, abbreviated criteria, and the Serum-Pleural Effusion Albumin Gradient (SPAG).\n* Determine the most common underlying causes of lung fluid across different stages of kidney disease.\n* Identify which diagnostic formula is the most accurate for CKD patients, helping doctors avoid misdiagnosis and provide better, more targeted treatments.",[25,120],"Chronic Kidney Disease",[122,123,124,125,126,127,128],"Light's Criteria","Serum-Pleural Effusion Albumin Gradient (SPAG)","Transudate","Exudate","Thoracentesis","Uremic Pleuritis","Hemodialysis","NOT_YET_RECRUITING","2026-04-17",{"date":132,"type":35},"2026-04-23",{"date":134,"type":21},"2026-05",{"date":136,"type":21},"2027-06",{"name":138,"class":42},"Assiut University",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":54,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":43},"100573097","confocal-laser-endomicroscopy-guided-medical-thoracoscopy-for-the-diagnosis-of-pleural-disease-100573097","NCT06741839","Confocal Laser Endomicroscopy Guided Medical Thoracoscopy for the Diagnosis of Pleural Disease","Efficacy and Safety of Confocal Laser Endomicroscopy Guided Medical Thoracoscopy for the Diagnosis of Pleural Disease: a Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Evidence of exudative pleural effusion in which a specific diagnosis could not be determined using clinical, radiological, laboratory, or cytological examinations\n* Willingness to participate in the study and undergo an invasive procedure.;\n\nExclusion Criteria:\n\n* Pleural thickening or pleural-based mass without pleural effusion on radiologic examination;\n* Hemodynamic instability;\n* Presence of parapneumonic effusion;\n* Any contraindication to pleural biopsy or semirigid thoracoscopy;\n* Participation in other studies within three months without withdrawal or termination.",{"count":147,"type":21},158,[91],"A prospective multicenter randomized controlled trial was conducted to evaluate the efficacy and safety of thoracoscopic biopsy guided by confocal optical real-time microscopic imaging (nCLE) in the diagnosis of fibrinal pleurisy of unknown etiology. Patients with fibrinous pleurisy of unknown etiology who were to undergo thoracoscopic pleural biopsy were enrolled and informed consent was signed. Subjects were randomized to either the nCLE guided biopsy Group (Group A) or the visual biopsy group (Group B) according to the randomization table (1:1 ratio). nCLE was used to probe the benign and malignant status of pleural lesions, compare the consistency of random pathological biopsy or nCLE guided biopsy with histopathological results, compare whether nCLE guided biopsy can reduce the number of thoracoscopic biopsies, and follow up short-term postoperative complications to evaluate its safety.",[151,25],"Pleural Diseases","2026-04-11",{"date":154,"type":35},"2026-04-15",{"date":156,"type":35},"2025-03-11",{"date":158,"type":21},"2027-05",{"name":160,"class":42},"China-Japan Friendship Hospital",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":170,"conditions":171,"keywords":174,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":181,"leadSponsor":182,"locationsCount":4},"100632455","evaluation-of-transthoracic-ultrasonography-in-differentiating-pleural-effusions-100632455","NCT07513909","Evaluation of Transthoracic Ultrasonography in Differentiating Pleural Effusions","Evaluation of Transthoracic Ultrasonography in Differentiating Exudative From Transudative Pleural Effusions","Inclusion Criteria:\n\n* Adult patients aged ≥18 years of either sex\n* Clinically and radiologically documented pleural effusion (confirmed by chest X-ray and\u002For thoracic ultrasound)\n* Patients scheduled for diagnostic or therapeutic thoracentesis as part of their standard clinical care\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Patients with a history of prior pleural interventions, including chemical or surgical pleurodesis or previous chest tube insertion on the affected side\n* Patients with absolute contraindications to thoracentesis (e.g., uncorrectable coagulopathy, uncooperative patients, or hemodynamic instability)\n* Poor transthoracic ultrasound window preventing adequate evaluation of the pleural space (e.g., due to severe obesity, extensive subcutaneous emphysema, or chest wall deformities)\n* Patients with traumatic hemothorax.",{"count":169,"type":21},90,"Pleural effusion is a condition where excess fluid builds up in the space between the lungs and the chest wall. To properly treat this condition, doctors must determine if the fluid is a \"transudate\" (usually resulting from systemic conditions like heart failure or liver disease) or an \"exudate\" (often resulting from local issues like infections, inflammation, or cancer). The standard method to classify this fluid involves inserting a needle into the chest to draw out a sample for laboratory testing, a procedure known as thoracentesis.\n\nWhile laboratory fluid analysis is highly accurate, the needle procedure carries some inherent procedural risks. This observational study aims to evaluate whether non-invasive imaging tests, specifically chest ultrasound, can accurately determine if the fluid is a transudate or an exudate.\n\nResearchers will enroll adult patients presenting with pleural effusion at Assiut University Hospital. As part of their diagnostic workup, participants will undergo a chest ultrasound and a standard diagnostic thoracentesis (fluid draw) within 24 to 48 hours of each other. The study will then evaluate the features seen on the ultrasound against the laboratory fluid analysis (the current gold standard) to see how well the non-invasive imaging performs in identifying the specific type of pleural effusion.",[25,172,173],"Transudative Pleural Effusion","Exudative Pleural Effusion",[175,176,124,125,122,126],"Chest Ultrasound","Computed Tomography","2026-04-08",{"date":179,"type":35},"2026-04-13",{"date":134,"type":21},{"date":136,"type":21},{"name":138,"class":42},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":191,"conditions":192,"keywords":195,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":43},"100593924","pleural-effusion-biomarkers-in-lung-adenocarcinoma-patients-100593924","NCT07012759","Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients","Novel Pleural Effusion Biomarkers Screening and Evaluation in Lung Adenocarcinoma Patients","Inclusion Criteria:\n\n* Patients requiring thoracentesis for pleural effusion drainage as determined by a physician based on clinical need.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients under the age of 18.\n* Patients with malignancies other than lung adenocarcinoma.",{"count":117,"type":21},"This project aims to assess the expression levels of novel molecular markers identified through screening in clinical samples of malignant pleural effusion, to evaluate the feasibility and clinical utility of these markers as potential diagnostic genes for lung adenocarcinoma.",[193,194,25],"Biomarkers","Lung Adenocarcinoma",[27,196,197,198],"biomarkers","lung cancer","clinical diagnosis","2026-03-04",{"date":201,"type":35},"2026-03-05",{"date":203,"type":35},"2025-06-10",{"date":205,"type":21},"2026-12-31",{"name":207,"class":42},"Fu Jen Catholic University",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":54,"phases":217,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":230},"100584695","pleuroscopy-first-versus-thoracentesis-first-in-patients-with-suspected-malignant-pleural-effusions-100584695","NCT06892691","Pleuroscopy First Versus Thoracentesis First in Patients With Suspected Malignant Pleural Effusions","PERFECT-MPE","Inclusion Criteria:\n\n* Referral for diagnostic pleural procedure.\n* Age ≥ 18 years.\n* Suspected malignant pleural effusion (Suggestive radiologic appearance (based on computed tomography or positron emission tomography) OR suspected cancer with associated effusion.)\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Needs emergent drainage.\n* Pleural effusion is known to be malignant.\n* Suspected transudative, infectious or inflammatory effusion etiology.\n* Having prior inconclusive\u002Fnon-diagnostic thoracentesis or pleuroscopy.\n* Patient is deemed by the clinical team to be more appropriate for VATS biopsy.\n* Terminally ill patients in whom a diagnosis will not change management, or who is unlikely to be a candidate for oncological treatment due to significant comorbidities.\n* Pregnancy",{"count":216,"type":21},98,[91],"This is a randomized control trial of patients with suspected malignant pleural effusions to compare whether patients who have a thoracentesis or pleuroscopy (pleural biopsy) obtain an adequate biopsy, achieve a diagnosis, and begin cancer-directed therapy faster.",[25,220],"Cancer","2026-02-02",{"date":223,"type":35},"2026-02-04",{"date":225,"type":35},"2025-03-24",{"date":227,"type":21},"2026-09-17",{"name":229,"class":42},"Icahn School of Medicine at Mount Sinai",2,{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":54,"phases":240,"briefSummary":241,"conditions":242,"keywords":247,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":43},"100568824","evaluation-of-the-efficacy-of-diagnostic-support-algorithms-in-chest-x-rays--luana-trial-100568824","NCT06686251","Evaluation of the Efficacy of Diagnostic Support Algorithms in Chest X-rays- LuAna Trial","Evaluation of the Efficacy of Diagnostic Support Algorithms in Chest X-rays - LungAnalysis (LuAna): LuAna Stepped Wedge Trial","Inclusion Criteria:\n\n* Non-reported chest X-rays (XRts) of individuals aged over 18 years.\n* Individuals images with respiratory complaints.\n* Chest X-rays taken during the presence of these respiratory symptoms or while being followed up for respiratory disease.\n* Chest X-rays taken on any X-ray machine.\n* Chest X-rays that include at least one frontal view of the chest.\n\nExclusion Criteria:\n\n* Those whose chest X-ray was performed due to a history of trauma, pre-operative risk assessment, lung cancer screening, or exclusively for verifying the correct positioning of a peripheral intravenous catheter (PICC).\n* Chest X-rays with technical quality below the minimum required for proper interpretation and diagnosis.\n* Cases without at least one frontal view.\n* X-rays printed on regular paper.",{"count":239,"type":21},1470,[91],"This study aims to evaluate whether the use of AI as a physician support tool is associated with an increase in the detection rate of chest radiographic findings in adults with respiratory complaints, compared to diagnosis performed exclusively by doctors, without AI support. This is a cluster-randomized clinical trial, following the stepped wedge design, and adhering to the guidelines of the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT). In this study, the Diagnostic Support Solution for Chest X-rays - LungAnalysis (LuAna), developed by the Hospital Israelita Albert Einstein (HIAE) within the PROADI-SUS Banco de Imagens, was used.\n\nThe clinical trial will be conducted in multiple centers with a diverse population from the public health system, to ensure that the algorithms are validated across a broad demographic profile. The expected benefits are significant, providing greater security for patients, increasing doctors' confidence in interpreting chest X-rays, promoting efficiency and cost savings for healthcare services, and offering promising prospects for other AI applications in imaging diagnostics.",[243,244,25,94,245,246],"Consolidation","Lung Injury","Cardiomegaly","Edema Lung",[248,249,250],"Artificial Intelligence","Chest X-ray","Stepped wedge trial","2026-01-29",{"date":221,"type":35},{"date":254,"type":35},"2026-01-05",{"date":256,"type":21},"2026-12-01",{"name":258,"class":42},"Hospital Israelita Albert Einstein",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":54,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":278,"locationsCount":80},"100349559","gravity-versus-vacuum-based-indwelling-tunneled-pleural-drainage-system-100349559","NCT03831386","Gravity Versus Vacuum Based Indwelling Tunneled Pleural Drainage System","The Impact of a Gravity Versus Vacuum Based Indwelling Tunneled Pleural Drainage System on Pain: A Multicenter, Randomized Trial","NEWTON","Inclusion Criteria:\n\n* Clinical indications for placement of IPC for malignant pleural effusion\n\n  a. Pleural effusion with symptomatic improvement in dyspnea after drainage of ipsilateral effusion\n* Clinically confident symptomatic malignant pleural effusion\n\n  1. Histocytological proof of pleural malignancy\n  2. Recurrent large pleural effusion in context of histologically proven cancer outside the pleural space\n* Plans for placement of IPC within ten days of enrollment\n* Age \\> 17 years\n* Sufficient fluid on ultrasound to allow for safe insertion of IPC\n\nExclusion Criteria:\n\n* Recent (less than 60 days) thoracic surgery or chest trauma causing chronic pain\n* Pregnant or lactating mothers\n* Previous ipsilateral chemical pleurodesis\n* Current contralateral indwelling pleural catheter\n* Known rib or thoracic skeletal metastasis causing pain\n* Concern for active pleural infection\n* Respiratory failure\n* Irreversible bleeding diathesis\n* Inability to provide care for indwelling tunneled pleural catheter\n* Significantly loculated pleural space precluding drainage of pleural space, for which IPC alone will likely not offer symptomatic benefit\n* Estimated life expectancy of \\\u003C 30 days (however, active enrollment in hospice program is not an exclusion criteria)\n* Inability to read\u002Funderstand\u002Fwrite in the English language\n* Inability to follow-up for appointments\u002Fprotocol\n* Subject has any clinical condition, diagnosis, or social circumstance that, in the opinion of the investigator would mean participation in the study would be contraindicated.\n* Enrollment in alternative pleural catheter trial that would preclude enrollment within this trial",{"count":268,"type":21},200,[91],"Malignant pleural effusion remains a debilitating complication of end stage cancer, which can be greatly improved by the introduction of the indwelling tunneled pleural catheter (IPC). However, there is no standard of care regarding drainage and limited data on the utility of different drainage techniques. In addition, many patients develop discomfort and chest pain during drainage. The investigators propose to evaluate gravity drainage and suction drainage on quality of life measures and outcomes.",[25],"2025-12-09",{"date":274,"type":35},"2025-12-17",{"date":276,"type":35},"2019-01-31",{"date":205,"type":21},{"name":279,"class":42},"Johns Hopkins University",{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":17,"minAge":287,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":54,"phases":291,"briefSummary":292,"conditions":293,"keywords":294,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":43},"100612068","effect-of-bubble-positive-expiratory-pressure-and-segmental-breathing-versus-incentive-spirometry-in-pleural-effusion-100612068","NCT07248774","Effect of Bubble Positive Expiratory Pressure and Segmental Breathing Versus Incentive Spirometry in Pleural Effusion","Effect of Bubble Positive Expiratory Pressure and Segmental Breathing Versus Incentive Spirometry on Lung Expansion and Dyspnea in Children With Pleural Effusion","Inclusion Criteria:\n\n* Age 5 to 16.\n* Suffering from Pleural effusion or hydrothorax.\n* Thoracic drainage system in situ for 24 hours.\n* Either gender will be included.\n* Patients without any other co-existing illness.\n\nExclusion Criteria:\n\n* Any other pulmonary pathology that does not fit the diagnostic criteria of Pleural Effusion.\n* Participants with unbearable chest pain, chylothorax, hemothorax, pneumothorax, chest trauma or rib fracture.\n* Participants with other comorbidities leading to pleural effusion.\n* Patients who have chest musculoskeletal deformities.","5 Years","16 Years",{"count":290,"type":21},40,[91],"Conducted as a randomized clinical trial, this study will include 40 pediatric participants aged 5-16, recruited from Gulab Devi Chest Hospital and Children's Hospital, Lahore. Participants will be randomly divided into two groups: one receiving Bubble PEP with Segmental Breathing and the other using Incentive Spirometry, both combined with conventional chest physiotherapy and mobility. Outcome measures, including lung expansion (via X-ray), dyspnea (assessed using the Pediatric Dyspnea Scale), chest expansion (measured with a measuring tape), oxygen saturation (SpO₂), and respiratory rate, will be recorded pre- and post-intervention. The study hypothesises that the Bubble PEP and Segmental Breathing approach may offer a cost-effective and efficient alternative to Incentive Spirometry, particularly for patients who cannot afford mechanical devices. Statistical analysis will be performed using SPSS version 2023 to determine the intervention's effects.",[25],[295],"Pleural effusion, PEP, Segmental Breathing, Dyspnea","2025-11-18",{"date":298,"type":35},"2025-11-25",{"date":300,"type":35},"2025-10-28",{"date":302,"type":21},"2026-01-15",{"name":304,"class":42},"Riphah International University",{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":54,"phases":314,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":43},"100540267","normal-saline-flushing-with-and-without-heparin-lock-in-maintaining-small-bore-intercostal-chest-catheter-icc-patency-100540267","NCT06314620","Normal Saline Flushing With And Without Heparin Lock In Maintaining Small Bore Intercostal Chest Catheter (ICC) Patency","Safety And Efficacy Of 8 Hourly Normal Saline Flushing With And Without Heparin Lock In Maintaining Small Bore Intercostal Chest Catheter (ICC) Patency ; A Prospective Pilot Study","SENSHIP","Inclusion Criteria:\n\n• All patients admitted in medical wards for pleural effusion who had small bore intercostal catheters inserted.\n\nExclusion Criteria:\n\n* Patients with hydropneumothorax with small bore intercostal catheters\n* Patients with septated effusion planned for intrapleural fibrinolysis\n* Patients with severe coagulopathy\n\n  * INR ≥ 1.5\n  * PT \\> 37s\n  * aPTT \\> 100s\n* Patients with thrombocytopenia of less than 50 x 109\u002FL\n* Patients who has not consented to be involved in the study\n* Patients with indwelling pleural catheters\n* Unconscious patients will be excluded from this study\n* Patients with poor GCS score will be excluded from this study",{"count":290,"type":21},[91],"Pleural diseases are among the most common clinical problems encountered in healthcare settings in Malaysia and even worldwide. Most patients presented in a hospital setting with pleural diseases will need pleural aspirations or thoracentesis and chest drains for a variety of reasons. Healthcare providers will often be exposed to patients requiring pleural drainage hence it is important to be aware of safe techniques and procedures of insertion and also maintaining the pleural drainage systems to yield beneficial results.\n\nMost often, smaller catheters were deemed to be less effective in view of slower drainage rates and associated with high risk of blockage. However presently , in tertiary hospital settings small bore intercostal chest catheters (SBICC) have become an alternative to large bore intercostal catheters (LBICC). SBICC has been found to be equally effective, less painful and easily tolerated by patients. Hence, proper maintenance of SBICC should be undertaken to reduce rates of occlusion and to yield most benefits from the pleural aspirations procedures.\n\nBritish Thoracic Society in their latest guidelines recommends the use of small bore intercostal chest drain as the first choice in draining pleural effusions.\n\nThe success of draining pleural effusions with a SBICC has shown variable rates of success among different studies conducted. Most common issues faced are drain blockage and drain dislodgement.\n\nThere is limited data comparing the use of normal saline flushing versus fibrinolytic drug lock in maintaining patency of small bore intercostal chest drains in draining pleural effusions. This has lead us in conducting this research to compare the rates of partial or complete occlusions among normal saline flush with and without heparin saline lock in maintaining the patency of small bore intercostal chest catheter among patients with pleural diseases in Hospital Canselor Tuanku Muhriz, UKM requiring chest drains insertion.",[25],"2025-11-17",{"date":319,"type":35},"2025-11-19",{"date":321,"type":35},"2024-03-15",{"date":323,"type":21},"2027-06-01",{"name":325,"class":42},"National University of Malaysia",{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":332,"eligibilityCriteria":333,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":54,"phases":336,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":339,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":43},"100535128","virtual-reality-distraction-during-small-bore-intercostal-chest-drain-insertion-100535128","NCT06247800","Virtual Reality: Distraction During Small Bore Intercostal Chest Drain Insertion","Virtual Reality: Satisfaction and Tolerability as a Distraction During Small Bore Intercostal Chest Drain Insertion an Open Label Randomized Control Trial","VR-STICH","Inclusion Criteria:\n\n* All participants undergoing ICC insertion\n* Participants who could understand and give consent\n\nExclusion Criteria\n\n* Participants who are unable to understand or give consent\n* Ventilated patients\n* Participants who are not comfortable wearing VR device\n* Participants who are unable to communicate (illiterate, had hearing impairment, mute, blind or had memory impairment)\n* Participants with craniofacial deformity\n* Participants who are on sedative medication\n\nTraumatic or post Motor Vehicular Accident patient Participants undergoing Indwelling pleural catheter insertion Participants with anxiety disorder\n\nExclusion Criteria:\n\n\\-",{"count":335,"type":21},80,[91],"Intercostal chest drain (ICC) insertion is a common procedure done worldwide to treat and diagnose pleural disease. It is used to evacuate fluid, blood, or air in the cavity from a myriad of causes namely pleural effusions of different etiologies, empyema, hemothorax, chylothorax and pneumothorax. It also functions as a route for antibiotics, pleurodesis and fibrinolytics. Hippocrates, whose practiced medicine 2,400 years ago, is often credited with being the first to insert a metal tube into the pleural region to drain fluid. It wasn't until the 19th century that a closed drainage system was properly documented in the literature, although open drainage remained to be the norm for quite some time.\n\nIn the past, large-bore tubes (24-32 F) were recommended in nearly all circumstances and were inserted using a blunt dissection technique. However, during the past two decades, small-bore catheters have become increasingly popular. They were first used to drain abdominal collections and have now been adopted for use in draining the pleural cavity utilizing the needle and guide wire Seldinger procedure, typically with radiological guidance. In addition to that, Seldinger technique allow us to insert the catheter at lower intercostals spaces without injury to the diaphragm or abdominal organs, thereby ensuring patient safety.",[25],{"date":319,"type":35},{"date":341,"type":35},"2024-02-01",{"date":343,"type":21},"2026-12-25",{"name":325,"class":42},{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":54,"phases":354,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":43},"100557458","clinical-utility-of-portable-dynamic-chest-x-ray-ddr-in-the-icu-100557458","NCT06538376","Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU","Clinical Utility of Portable Dynamic Chest X-Ray (DDR) in the ICU: Clinical Trial to Demonstrate the Feasibility of Deploying DDR Technology in the ICU - A Study to Prove Its Increased Diagnostic Value","Inclusion Criteria: Participants must meet all the following inclusion criteria to participate in this study:\n\n* Adults (at least 18 years of age) including both intubated\u002Fventilated and non-intubated patients\n* Likely to have pathology related to either, abnormal diaphragmatic excursion and lung aeration, pulmonary perfusion, increased lung water content or all the above, as well as for cricopharyngeal dysfunction\u002Fswallowing difficulties at risk for aspiration.\n* The subject or a legally authorized representative has provided written informed consent.\n\nExclusion Criteria: Candidates meeting any of the exclusion criteria at baseline will be excluded from study participation. These criteria are:\n\n* Special populations, including women with known pregnancy, prisoners, or institutionalized individuals\n* Patients where additional radiation is clinically contraindicated\n* Care team does not provide assent for approaching patient\u002Fsurrogate\n* For women of child-bearing potential, defined as premenopausal women, a pregnancy test will be administered to determine pregnancy status and confirm eligibility for the study. A pregnancy test will NOT be administered to women who are post-menopausal or have documentation of surgical sterilization.",{"count":353,"type":21},230,[91],"Dynamic digital radiography (DDR) is a new advanced version of chest radiography that captures dynamic images at a rate of 15 frames per second. It is coupled with an analytical software that allows it to provide more advanced measures of lung motion, ventilation, and perfusion compared to traditional chest radiography. While implementation of DDR fixed machines are beginning elsewhere in the US, this trial involves the first applications of an FDA-approved portable DDR machine, for use at the bedside in the ICU.\n\nThe goal of this clinical trial is to determine the feasibility and safety of portable DDR technology in the ICU, as well as to evaluate the improved clinical diagnostic value of the portable DDR system over current standards of care.\n\nParticipants will receive one to three sets of DDR images, which will then be compared to their clinical gold standard exams (such as chest x-rays, CTs, or VQ scans) to assess and improve the precision and accuracy of measurements such as diaphragmatic motion, lung movement, and perfusion.",[357,358,359,25,360,361,362,363,364,365,366,94,367,368],"Pulmonary Edema","Pneumonia","Atelectasis","Acute Rejection of Lung Transplant (Disorder)","Airway Obstruction","Rib Fractures","Acute Copd Exacerbation","Asthma COPD","Pulmonary Embolism","Hemothorax","Mesothelioma","Diaphragmatic Paralysis",{"date":370,"type":35},"2025-10-29",{"date":372,"type":35},"2023-12-12",{"date":374,"type":21},"2027-11",{"name":376,"class":42},"Brigham and Women's Hospital",{"id":378,"slug":379,"hasResults":11,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":54,"phases":387,"briefSummary":388,"conditions":389,"keywords":393,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":43},"100589846","armstrong---air-entrainment-vs-standard-treatment-in-non-expandable-lung-100589846","NCT06959719","ARMSTRONG - Air entRainMent vS sTandard tReatment in nOn-expandable luNG","Air Entrainment vs. Standard Treatment in Non-Expandable Lung With Persistent Pleural Effusion: A Randomised Controlled Double-Blind Trial","ARMSTRONG","Inclusion Criteria:\n\n* Adults aged 18 years or older with a suspected or confirmed diagnosis of NEL and persistent pleural effusion.\n* Patients who are scheduled for pleural effusion drainage as part of their standard care.\n* Ability to adequately understand verbal or written information in English and provide informed consent in English.\n\nExclusion Criteria:\n\n* Patients with a history of pleurodesis or other procedures that may affect pleural dynamics.\n* Patients with active infections or other acute medical conditions that could interfere with the study.\n* Patient with multifactorial pain and high baseline score pain defined as VAS \\>= 5\n* Patients requiring IPC\n* Individuals with known contraindications to pleural drainage or air entrainment.\n* Patients who cannot provide informed consent in English, do not adequately understand verbal or written information in English or have special communication needs.",{"count":386,"type":21},41,[91],"This is a randomised controlled trial evaluating whether controlled air introduction into pleural space (air entrainment) during pleural effusion drainage reduces pain, improves patient satisfaction, and facilitates more effective drainage in patients with non-expandable lung (NEL).\n\nNEL lung is a common complication in patients with malignant or chronic pleural effusions, where the lung fails to fully re-expand after fluid removal due to pleural disease or fibrosis. In these patients, drainage often creates excessive negative pressure within the pleural cavity, leading to pain, vasovagal episodes, early termination of drainage, and the need for repeated procedures.\n\nThis study investigates a simple, safe, and low-cost intervention using a standard 3-way tap attached to the drainage system. By intermittently opening the tap to atmospheric air during drainage, air enters the pleural cavity in a controlled fashion, reducing negative pressure and potentially reducing pain, improving drainage tolerance, and minimising the need for repeated procedures.\n\nPleural effusion drainage is a common procedure in patients with advanced malignancy or chronic pleural disease. In patients with NEL, fluid removal creates a vacuum effect within the pleural space due to the inability of the lung to fully re-expand. This negative pressure is a key driver of severe procedural pain, vasovagal symptoms, and premature cessation of drainage. It may also necessitate multiple drainage procedures over a short period.\n\nCurrently, there are limited strategies to mitigate this problem, often relying on stopping the procedure prematurely or on analgesia, which does not address the underlying cause.\n\nThis trial evaluates the introduction of atmospheric air into the pleural space during drainage as a pragmatic, low-cost solution. The technique uses standard equipment - a 3-way tap - allowing air to be introduced safely and intermittently during drainage to reduce the vacuum effect.\n\nPatients undergoing therapeutic pleural drainage with an indwelling catheter or chest drain will be randomised in a 2:1 ratio to:\n\nStandard drainage care (control group)\n\nDrainage with intermittent controlled air introduction (intervention group)\n\nAir entrainment will be performed by briefly opening the 3-way tap to atmospheric air during drainage up to five times, based on patient discomfort and operator discretion. This aims to equalise pleural pressures, reduce pain, and improve drainage outcomes.\n\nRandomisation is weighted 2:1 towards the intervention group to maximise the number of patients who may benefit, following favourable preliminary data. Both patients and outcome assessors will be blinded to group allocation.\n\nOutcomes collected\n\nPrimary Outcomes:\n\nPatient-reported pain scores during drainage - Pain will be assessed using the Visual Analogue Scale (VAS), ranging from 0 to 10 cm, where 0 indicates \"no pain\" and 10 indicates \"worst imaginable pain.\" Higher scores represent a worse outcome.\n\nSecondary Outcomes:\n\nVolume of pleural fluid drained Number of pleural drainage procedures required Time interval between drainage procedures Incidence of complications (e.g., pneumothorax, re-expansion pulmonary oedema, infection) Reasons for incomplete drainage, including the presence and characteristics of non-expandable lung Patient-reported satisfaction with the drainage procedure",[390,391,25,392],"Non-expandable Lung","Trapped Lung","Malignant Pleural Effusions (Mpe)",[394,395,396,397,398],"air entrainment","trapped lung","non-expandable lung (NEL)","pleural effusion","malignant pleural effusion","2025-05-04",{"date":401,"type":35},"2025-05-07",{"date":403,"type":35},"2025-04-14",{"date":405,"type":21},"2026-10-30",{"name":407,"class":42},"Cambridge University Hospitals NHS Foundation Trust",{"id":409,"slug":410,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":416,"enrollmentInfo":417,"targetDuration":4,"studyType":54,"phases":418,"briefSummary":419,"conditions":420,"keywords":424,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":436,"locationsCount":43},"100588829","first-local-anaesthesia-thoracoscopy-for-pleural-effusion-diagnosis-100588829","NCT06946498","First Local Anaesthesia Thoracoscopy for Pleural Effusion Diagnosis.","Local Anesthesia Thoracoscopy as a First Line Approach in the Diagnosis of Suspected Malignant Pleural Effusion: FLAT Trial.","FLAT","Inclusion Criteria:\n\n* Undiagnosed pleural effusion with the character of a lymphocytic exudate\n\nExclusion Criteria:\n\n* Empyema\n* Transudate pleural effusion.\n* Central airway obstruction by tumor.\n* Existence of extensive adhesions that do not allow the development of iatrogenic pneumothorax and the safe entry of the thoracoscope.\n* Uncontrollable cough.\n* Acute respiratory failure and\u002For Hypercapnia.\n* Performance Status: 5","90 Years",{"count":117,"type":21},[91],"Non randomized study with two groups. The study group includes patients with suspected malignant pleural effusion, in whom the investigation of pleural effusion begins directly with pleural biopsy by Local Anesthesia Thoracoscopy (LAT).\n\nThe Control Group includes patients who come to the same hospital and are treated with the Standard of Care (SOC) strategies were used. Efficacy of LAT, Sensitivity, Hospitalization, time to diagnosis and general safety and comfort of the groups' subjects will be assessed.",[421,25,422,423],"Suspected Malignant Lung Neoplasm","Pleural Effusion, Malignant","Mesothelioma, Malignant",[425,426,427,428,367,429],"Malignant Pleural Effusion","Local Anesthesia Thoracoscopy","Medical Thoracoscopy","Lung cancer","Lymphocytic Exudate","2025-04-20",{"date":432,"type":35},"2025-04-27",{"date":434,"type":35},"2023-05-23",{"date":205,"type":21},{"name":437,"class":42},"National and Kapodistrian University of Athens",{"id":439,"slug":440,"hasResults":11,"nctId":441,"briefTitle":442,"officialTitle":442,"acronym":443,"eligibilityCriteria":444,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":447,"conditions":448,"keywords":451,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":230},"100513075","improvement-to-perform-thoracocentesis-after-a-specific-training-in-medical-students-with-the-supervised-use-of-an-augmented-reality-simulator-100513075","NCT05960747","Improvement to Perform Thoracocentesis After a Specific Training in Medical Students With the Supervised Use of an Augmented Reality Simulator","ARPEGES","Medical students :\n\nInclusion criteria:\n\n* Medical students between the 4th and 6th year of their medical course, working in the department of respirology at the University hospital of Strasbourg, France, without any prior experience of thoracocentesis.\n* Older than 18 years old\n* No opposition to participate to the study (signed consent form).\n\nExclusion criteria:\n\n\\- Student with a prior experience of pleural procedure (chest tube, thoracocentesis).\n\nPatients :\n\nInclusion criteria:\n\n* Patients requiring a first-time thoracentesis in routine care.\n* Older than 18 years old.\n* Speaking and understanding French.\n* Valid health insurance.\n* No opposition to participate to the study (signed consent form).\n\nExclusion criteria:\n\n* Patient with previous experience of pleural procedure (thoracocentesis, chest tube…).\n* Patient having a high-volume pleural effusion according to radiological\u002Fultrasound criteria.\n* Patient with low-volume pleural effusion according to radiological\u002Fultrasound criteria.\n* Patient with poor clinical tolerance of the pleural effusion(respiratory instability, dependence on ventilation machine with positive expiratory pressure…).\n* Patients with higher risk of complication during the procedure (BMI \\> 35 kg\u002Fm², with increased risk of bleeding…).\n* Contraindication to the use of Lidocaine.\n* Local infection.\n* Impossibility to provide detailed information to the patient.\n* Subject under legal protection.",{"count":446,"type":21},340,"Monocentric study, aiming to assess the improvement of medical students to perform a first-time thoracentesis after training using a specific training using an augmented virtual reality simulator, versus standard training.\n\nStudy population: medical students from the department of Respirology (University hospital of Strasbourg), performing their first thoracocentesis in patients having an indication for a first-time thoracocentesis.\n\nThis is not an interventional study, no change in patient course being induced because of the study.\n\nAfter the procedure: use of specific surveys for the patient and for medical students to assess the patient's pain, the patient and the medical student level of anxiety, and the student ability during the procedure.",[25,449,450],"Frist Time Indication to Perform a Thoracentesis","Medical Student Training",[126,452,453],"Augmented virtual reality simulator","Medical student training","2025-03-31",{"date":456,"type":35},"2025-04-03",{"date":458,"type":35},"2024-02-15",{"date":460,"type":21},"2026-02",{"name":462,"class":42},"University Hospital, Strasbourg, France",{"id":464,"slug":465,"hasResults":11,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":469,"eligibilityCriteria":470,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":54,"phases":473,"briefSummary":474,"conditions":475,"keywords":477,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":80},"100529963","strategy-for-prompt-and-effective-thoracentesis-in-the-emergency-department-100529963","NCT06180603","Strategy for Prompt and Effective Thoracentesis in the Emergency Department","Strategy for Prompt and Effective Thoracentesis in the Emergency Department: A Multicenter Randomized Clinical Trial","SPEEDTAP","Inclusion Criteria:\n\n* Patients ≥ 18 years admitted to the ED\n* Pleural effusion detected by any imaging modality (e.g., bedside ultrasound, chest x-ray, computed tomography)\n* Clinically justified need for thoracentesis ( symptomatic relief and\u002For define the etiology of the effusion\n* Without contraindication for thoracentesis in the emergency department (e.g., anticoagulant treatment)\n\nExclusion Criteria:\n\n* Life-threatening respiratory distress\n* Not able to give consent\n* Previous pleurodesis\n* Effusion does not appear free-flowing due to septations or loculations \u002F suspected empyema\n* Prior enrollment in the trial\n* If randomization is not possible because decision to insert a pigtail catheter is made in the radiology department",{"count":472,"type":21},188,[91],"The SPEEDTAP-trial is a prospective, randomised, investigator-initiated, multicenter, clinical superior trial investigating two thoracentesis methods in four emergency departments (ED) in Central Denmark Region. Patients are randomised to either manual fluid removal in the ED or passively fluid drainage using gravity in the radiology department (standard of care). Primary outcome: time from clinical indication to complete drainage and 188 patients will be included. Key secondary outcomes include length of stay, ED admission to ED discharge and safety end-points.",[25,151,476],"Heart Failure",[126,478,479],"Emergency department","Treatment methods","2024-12-04",{"date":482,"type":35},"2024-12-05",{"date":484,"type":35},"2024-01-15",{"date":486,"type":21},"2025-12-31",{"name":488,"class":42},"University of Aarhus",{"id":490,"slug":491,"hasResults":11,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":496,"targetDuration":498,"studyType":22,"phases":4,"briefSummary":499,"conditions":500,"keywords":507,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":43},"100500545","comparing-the-diagnostic-sensitivity-and-specificity-of-pleural-fluid-n-terminal-pro-b-type-natriuretic-peptide-nt-probnp-and-other-biochemical-gradient-criteria-in-distinguishing-heart-failure-and-non-heart-failure-related-pleural-effusions-centre-study-100500545","NCT05797649","Comparing the Diagnostic Sensitivity and Specificity of Pleural Fluid N-Terminal Pro B-type Natriuretic Peptide (NT-proBNP) and Other Biochemical Gradient Criteria in Distinguishing Heart Failure and Non-heart Failure Related Pleural Effusions (CENTRE Study)","Comparing N-terminal-proB-type Natriuretic Peptide with Other Diagnostic Criteria in Discriminating Heart Failure-associated from Non-heart Failure-associated Pleural Effusions","Inclusion Criteria:\n\n* Patients hospitalized for heart failure and pleural effusion\n* Pleural tapping indicated for pleural fluid analysis.\n* Aged 18 years old or above\n\nExclusion Criteria:\n\n* History of intrapleural therapy (including talc and fibrinolytic) in the ipsilateral pleural space.\n* History of surgical decortication or pleurodesis in the ipsilateral pleural space.\n* Ipsilateral thoracic or cardiac surgery in the past 3 months.\n* Failure to obtain informed consent due to the patient's refusal or cognitive impairment.",{"count":497,"type":21},120,"24 Months","To assess the discriminative properties of pleural fluid (PF) N-terminal-proB-type-natriuretic-peptide (NTproBNP) levels in identifying heart failure (HF)-associated pleural effusions (PE).",[25,476,501,502,503,504,505,506],"Malignant Neoplasm","Fluid Overload","Hypoalbuminemia","Renal Failure","Cirrhosis","Infections",[508,509,510,511,512,513,514,515],"pleural fluid","heart failure","malignancy","cancer","echocardiography","infection","tuberculosis","respiratory medicine","2024-11-11",{"date":518,"type":35},"2024-11-13",{"date":520,"type":35},"2023-07-01",{"date":522,"type":21},"2025-11-30",{"name":524,"class":42},"Chinese University of Hong Kong",{"id":526,"slug":527,"hasResults":11,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":531,"eligibilityCriteria":532,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":533,"targetDuration":4,"studyType":54,"phases":534,"briefSummary":535,"conditions":536,"keywords":539,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":4},"100561405","chest-drain-insertion-assisted-by-virtual-reality-100561405","NCT06589739","Chest Drain Insertion Assisted by Virtual Reality","Drainage Thoracique Assisté Par Un Casque De Réalité Virtuelle","CASVIA","Inclusion Criteria:\n\n* Indication of chest drain insertion for pleural effusion or primary spontaneous pneumothorax\n* Patient who received clear and loyal information abotu the study protocol\n* Patient who consented to participate to the study\n* Patient aged 18 years old or older\n* Patient affiliated to the french health system\n\nExclusion Criteria:\n\n* Patient aged less than 18 years old\n* Patient in emergency situation\n* Patient with severe heart condition\n* Patient allergic to silicone\n* Patient with severe psychiatric or mental disorder\n* patient with binocular vision anomaly\n* patient with pacemaker or defibrillator\n* patient wearing a hearing aid that cannot be removed\n* Patients under the influence of alcohol or drugs, nausea, fatigue, emotional or anxiety disorders, migraine, headaches, infectious disease\n* Patient with past medical history of epilepsia or convulsion\n\n  \\-- Persons covered by articles L. 1121-5 and L1121-8 of the French Public Health Code:\n  * Pregnant, parturient or breast-feeding women,\n  * Persons of full age subject to a legal protection measure (guardianship, curatorship, safeguard of justice)\n  * adults unable to give their consent\n  * Persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care under articles L. 3212-1 and L. 3213-1.\n* Person able to give consent but unable to write\n* Person able to give consent but unable to read French\n* Patient unable to consent to the study",{"count":290,"type":21},[91],"Clinical study aiming to investigate the potential benefit of the use of virtual reality helmet as a distractor during chest drain insertion to alleviate patients\\' pain and anxiety",[537,538,25],"Pneumothorax Spontaneous Primary","Pneumothorax Spontaneous Secondary",[540,541,542,543,544],"virtual reality","chest drain","pain management","chest tube","anxiety management","2024-09-06",{"date":547,"type":35},"2024-09-19",{"date":549,"type":21},"2024-10-01",{"date":551,"type":21},"2025-10-01",{"name":553,"class":42},"Central Hospital, Nancy, France",{"id":555,"slug":556,"hasResults":11,"nctId":557,"briefTitle":558,"officialTitle":558,"acronym":4,"eligibilityCriteria":559,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":560,"targetDuration":4,"studyType":54,"phases":561,"briefSummary":562,"conditions":563,"keywords":564,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":4},"100523696","ultrasound-guided-pigtail-catheter-versus-intercostal-tube-drainage-of-non-traumatic-exudative-pleural-effusion-100523696","NCT06099054","Ultrasound-guided Pigtail Catheter Versus Intercostal Tube Drainage of Non-traumatic Exudative Pleural Effusion","Inclusion Criteria:\n\n1. Age \\> 18 years.\n2. Non-traumatic non-iatrogenic exudative pleural effusion necessitating drainage.\n3. Loculated pleural effusion where positive colour doppler sign is preserved\n\nExclusion Criteria:\n\n1. Traumatic or iatrogenic pleural effusion.\n2. Transudative pleural effusion (subjected to treatment of the underlying cause and diuretic therapy).\n3. Exudative pleural effusion amenable for medical treatment\n4. Large-volume, easily accessible, free non-loculated empyema.\n5. Pleural infections with loculated pleural effusion but showing negative colour doppler sign.\n6. Malignant pleural effusion with potentially inexpnasible underlying lung (thick pleural peel, central airway obstruction), life expectancy \\\u003C 1 month or asymptomatic.\n7. Patients with uncorrected bleeding tendency (INR \\> 1.5, Platelet count \\\u003C 50.000\u002Fmm3).\n8. Inability or refusal to sign written consent.",{"count":335,"type":21},[91],"Primary Aims:\n\nTo compare the performance of pigtail catheter to that of ICT in drainage of pleural effusion of medical aetiology regarding:\n\n1. Various complications(mainly wound pain) that result from either therapeutic approach.\n2. Success of complete drainage.\n3. Compare the duration needed for complete drainage.\n\nSecondary Aims:\n\nTo evaluate both techniques in terms of:\n\n1. Degree of patient's mobility that either technique permits.\n2. Percentage of patients that can be managed on outpatient settings by either approach",[25],[565],"pigtail versus intercostal tube","2023-10-23",{"date":568,"type":35},"2023-10-25",{"date":570,"type":21},"2023-12-01",{"date":572,"type":21},"2028-05-25",{"name":138,"class":42},{"id":575,"slug":576,"hasResults":11,"nctId":577,"briefTitle":578,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":54,"phases":581,"briefSummary":582,"conditions":583,"keywords":4,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":4},"100488590","role-of-ultrasound-elastography-in-pleural-effusion-100488590","NCT05642091","Role of Ultrasound Elastography in Pleural Effusion","Inclusion Criteria:\n\n.patients with pleural effusion above18 year\n\nExclusion Criteria:\n\n* patients who refuse to undergone further investigations to reach final diagnosis of cause of pleural effusion\n\n.patients with intercostal tube inserted in the effusion before enrollment in the study.",{"count":335,"type":21},[91],"Diagnostic performance of u.s elastography in pleural effusion",[25],"2022-12-06",{"date":586,"type":35},"2022-12-08",{"date":588,"type":21},"2022-12-13",{"date":590,"type":21},"2026-08",{"name":138,"class":42}]